1 published article · Updated continuously
16 trials tracked for neuropathy: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 236 citations.
Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical data regarding chemotherapy-induced neuropathy and related interventions show varied outcomes. In studies evaluating calcium gluconate, research identified specific cumulative oxaliplatin doses (approximately 8.0 to 8.4) that could be administered without dose-limiting chronic neurotoxicity (p=0.89) 1.
Assessments of acetyl-L-carnitine hydrochloride for neuropathy did not show statistically significant differences compared to placebo in terms of FACT-Taxane Neurotoxicity Model-adjusted scores (p=0.17), FACT-Trial Outcome Index (TOI) functional status (p=0.92), or FACIT-fatigue scores (p=0.20) 2.
In trials evaluating Carboplatin, the assessment of Paclitaxel/Carboplatin induced peripheral neuropathy via EORTC QLQ-CIPN20 showed no significant difference between groups (p=0.21). Additionally, very low percentages of patients required chemotherapy delays or dose reductions due to peripheral neuropathy 3.
AI synthesis of 4 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
